Lelystad

Researchers are investigating the effectiveness of two different concentrations of Atropine eye drops, 0.05% and 0.5%, in slowing the progression of axial length in European children aged 6 to 11 years with progressive myopia. Progressive myopia is increasing worldwide and can lead to serious complications such as myopic macular degeneration, retinal detachment, and glaucoma, which may cause low vision or blindness. The study aims to compare the safety, adherence, and reasons for nonresponse to these treatments over a long period. Participants will receive either Atropine 0.05% or Atropine 0.5% eye drops daily for three years. After this treatment phase, there will be a two-year observational follow-up period without study medication to monitor the longer-term effects. The study is double-masked and randomized, meaning neither the participants nor the researchers know which treatment is being given, to ensure unbiased results. During the study, children will undergo regular assessments including measurements of axial length to track eye growth, vision tests, and monitoring for side effects or adherence to the treatment. The main outcome measured is the change in axial length from the start of the study to 36 months. Researchers will also evaluate safety and reasons why some children might not respond to the treatment. The total participation lasts five years, including treatment and observation.